ScoreWhy is Titan Biotech Ltd ?
1
Company has a Debt to Equity ratio (avg) of 0.02 times
2
Poor long term growth as Operating profit has grown by an annual rate -5.17% of over the last 5 years
3
With a growth in Operating Profit of 98.66%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- PBT LESS OI(Q) At Rs 8.17 cr has Grown at 123.84%
- PAT(Q) At Rs 6.73 cr has Grown at 66.2%
- DEBTORS TURNOVER RATIO(HY) Highest at 9.03 times
4
With ROE of 16.5, it has a Very Expensive valuation with a 10.2 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 429.83%, its profits have risen by 38.7% ; the PEG ratio of the company is 1.6
5
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Titan Biotech should be less than 10%
- Overall Portfolio exposure to Specialty Chemicals should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Specialty Chemicals)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Titan Biotech for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Titan Biotech
430.24%
6.55
65.63%
Sensex
-5.91%
-0.44
13.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.71%
EBIT Growth (5y)
-5.17%
EBIT to Interest (avg)
27.68
Debt to EBITDA (avg)
0.23
Net Debt to Equity (avg)
0.02
Sales to Capital Employed (avg)
1.19
Tax Ratio
28.11%
Dividend Payout Ratio
6.65%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
23.53%
ROE (avg)
19.48%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
62
Industry P/E
42
Price to Book Value
10.22
EV to EBIT
55.20
EV to EBITDA
48.15
EV to Capital Employed
10.03
EV to Sales
9.02
PEG Ratio
1.60
Dividend Yield
0.09%
ROCE (Latest)
18.17%
ROE (Latest)
16.46%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
PBT LESS OI(Q)
At Rs 8.17 cr has Grown at 123.84%
PAT(Q)
At Rs 6.73 cr has Grown at 66.2%
DEBTORS TURNOVER RATIO(HY)
Highest at 9.03 times
NET SALES(Q)
At Rs 48.83 cr has Grown at 38.84%
-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 1.87 cr
Loading Valuation Snapshot...
Here's what is working for Titan Biotech
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 8.17 cr has Grown at 123.84%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 6.73 cr has Grown at 66.2%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 48.83 cr has Grown at 38.84%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Debtors Turnover Ratio- Half Yearly
Highest at 9.03 times
in the last five half yearly periodsMOJO Watch
Company has been able to settle its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Titan Biotech
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 1.87 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Non Operating Income - Quarterly
Highest at Rs 2.11 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
